We’re talking about an Oxford Vaccine Group Com-Cov vaccine trial, launched in February with sites across the UK. It’s a study comparing COVID-19 vaccines scheduling combinations and it consists of more than 800 participants, aged 50 or older. Prof. Matthew Snape, Chief of investigation says that the reaction of mixing Pfizer and AstraZeneca doses brings rather fascinating mild to severe side effects. Typically, we either see them when not mixing, but here they seem to be more frequent. The good news is they don’t last long – within 48 hours after immunization. However, prof. Snape’s advice is:
The trial was randomly based on specific volunteers, so it’s possible younger aged groups will be more prevalent to such side effects. They were divided on a 4 dosing schedules at an either four- or 12-week interval, as follows:
First and second dose
With so many eyes focused on evaluation of this research, new results coming is more than crucial. Canadian provinces of Ontario and Quebec plan on trying a mixing schedule, due to concerns about AstraZeneca-Oxford vaccine blood clots. McMaster University associate professor and infectious disease specialist Dr. Zain Chagla was not involved in the study, yet commented:
It turns out mixing different doses isn’t really that safe. But in order to be honest, it has its benefits and isn’t explored entirely. Nowadays, we have several options and we can decide which of them will suit us best. You’d better have the chance to choose which COVID-19 vaccine to take, than no access to any of them. Definitely, things used to be worse when the COVID-19 pandemic started. It’s getting more likely to see a light at the end of the tunnel. Side effects from mixing schedules are an affordable enough price to pay, if we want all nightmares to end.
MVS Pharma GmbH is an innovative pharmaceutical start-up company, which researches in the area of reducing viruses and bacteria with plant based aerosols. Their special formula ensures the purity and the stability of the used ingredients during storage.
Liliya Ganeva is an article writer, who explores all the actual, up-to-date COVID-19 information, and the possibilities for producing aerosols made out of plants against respiratory viruses and bacteria.